NCT07921420: MF-300 for Treatment of Age-Related Sarcopenia
- State
- Not started
- Phase
- Phase 2
- People
- 225 planned
- Started
- 1 Jan 2027
- Primary completion
- 1 Jun 2028
- Arms
- Part A: MF-300 75 mg, Part B: MF-300 75 mg, Part B: MF-300 200 mg
- Results
- None posted
- 6 Nov 2026: Trial registered